[{"orgOrder":0,"company":"Bach Biosciences","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Licensing Agreement","leadProduct":"PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bach Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bach Biosciences \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Bach Biosciences \/ Point Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Bach Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The agreement provides POINT the exclusive global rights to commercialize the groundbreaking can-SEEK™ tumor targeting technology. With canSEEK™, POINT expands its theragnostic oncology pipeline to include PNT2004, a pan tumor treatment.

                          Product Name : PNT2004

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          October 11, 2020

                          Lead Product(s) : PNT2004

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Point Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank